<DOC>
	<DOCNO>NCT01155245</DOCNO>
	<brief_summary>This study investigate effect bone quality medication ( Teriparatide ) use treat people severe osteoporosis . Teriparatide bone formation therapy approve treatment postmenopausal osteoporosis Canada . Osteoporosis currently diagnose use bone mineral density ( BMD ) scan , measure amount mineral ( calcium etc ) bone ( high amount mineral , low fracture risk ) . Although BMD link bone strength use measure fracture risk , give information bone structure ( call bone geometry ) also tell u great deal fracture risk . Clinical trial show teriparatide increase BMD lumbar spine total hip , BMD forearm decrease 20 month therapy . Whether decrease BMD forearm suggest high risk wrist fracture change bone structure unclear . Bone biopsies pelvis do people take teriparatide show improvement bone geometry ( ie bone thickness increase trabecula ( small interconnecting rod bone ) , suggest change bone geometry wrist may occur well . Currently , new technology , high resolution pQCT ( HR-pQCT ) ass bone geometry without biopsy . Since bone strength affect BMD bone structure ( well material property ) , group interest examine change bone geometry forearm ( non-weight bearing site ) ankle ( weight bearing site ) postmenopausal woman osteoporosis receive 24 month teriparatide therapy . The investigator believe new approach measure bone strength help u good understand whether teriparatide different effect different bone site .</brief_summary>
	<brief_title>Teriparatide ( PTH ) Bone Strength Postmenopausal Women</brief_title>
	<detailed_description>This study investigate effect bone quality medication use treat severe osteoporosis . Teriparatide ( PTH ) bone formation therapy approve treatment postmenopausal osteoporosis Canada . It work induce new periosteal bone apposition , result improve bone geometry increase bone strength , change may capture bone mineral density ( BMD ) measurement . Randomized controlled trial show teriparatide increase BMD lumbar spine total hip , BMD forearm may decrease 20 month therapy . As data date publish change bone geometry radius either bone biopsy high resolution peripheral quantitative computer tomography ( HR-pQCT ) patient receive PTH therapy , unclear whether decline BMD distal radius observe PTH therapy indicative decrease bone strength , result increase width radius . It intention fill gap knowledge regard PTH affect BMD bone structure radius tibia postmenopausal woman severe osteoporosis . Examining two component enable u good understand effect teriparatide bone strength radius tibia , bone strength general , independent change BMD course treatment . The main objective study determine effect 24 month teriparatide therapy cortical thickness , trabecular thickness , trabecular number , trabecular separation BV/TV , measure HR-pQCT ( XtremeCT , Scanco Medical , Switzerland ) radius tibia postmenopausal woman osteoporosis . The primary outcome cortical thickness ; measure secondary outcome . The secondary objective determine effect 24 month teriparatide therapy moment inertia , connectivity index , bone strength , measure HR-pQCT calculate use finite element model analysis radius tibia postmenopausal woman osteoporosis . This open label study cohort postmenopausal woman take teriparatide baseline 24 month teriparatide therapy . Recruitment subject referral specialty clinic participate investigator . The postmenopausal woman study prescribed teriparatide accord recent Canadian product monograph Forteo™ . Participants undergo two ( 2 ) procedure five ( 5 ) separate occasion ( baseline , 6 month , 12 month , 18 month 24 month ) . The procedure HR-pQCT DEXA . In addition procedure , subject ask complete blood test part standard clinical practice . Blood drawn baseline 1 month . A follow phone call also make participant 1 , 6 , 12 month discuss update health status . With data , investigator hope provide good understanding change occur bone structure distal radius tibia teriparatide therapy .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>History fragility fracture OR High risk fracture OR Very low BMD ( Tscore ≤ 2.5 ) OR Failed intolerant bisphosphonates Baseline serum level calcium , urate , ALP , PTH , creatinine 25hydroxyvitamin D [ 25 ( OH ) D ] must within acceptable normal limit History skeletal irradiation Those increase risk osteosarcoma Diagnosis Paget 's disease History primary hyperparathyroidism Significant renal impairment Vitamin D deficiency On steroid cause secondary osteoporosis</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>HR-pQCT</keyword>
	<keyword>PTH</keyword>
</DOC>